Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapleural Bevacizumab and Cisplatin for Malignant Pleural Effusion in NSCLC
NCT01661790Phase 3Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2009
- Primary completion
- Jun 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in malignant pleural effusion (MPE) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Number of Participants With Complete Response and Partial Response. Started Aug 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT01661790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661790.